Methods of treating cardiomyopathy
A method of treating a cardiomyopathy in a subject includes administering to the subject a therapeutically effective amount of an agent that modulates contractile function in myocardial tissue of the subject.
1. A method of treating cardiomyopathy in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent that modulates contractile function in a myocardial tissue of the subject, the agent comprising a vector that includes a nucleic acid encoding a cMyBPC protein or a mutant cMyBPC protein thereof, wherein the mutant cMyBPC protein includes a triple S to D phosphorylation mutation and accelerates contraction in myocardial tissue of the subject or a triple S to A phosphorylation mutation and decreases contraction in myocardial tissue of the subject.
2. The method of claim 1 , the myocardial tissue comprising left ventricle cardiac tissue.
3. The method of claim 1 , the agent being administered directly to the myocardial tissue of the subject.
4. The method of claim 1 , the agent being administered to the subject's myocardial tissue at an amount effective to cause functional improvement in at least one of left ventricular end systolic volume, left ventricular ejection fraction, wall motion score index, left ventricular end diastolic length, left ventricular end systolic length, left ventricular end diastolic area, left ventricular end systolic area, or left ventricular end diastolic volume.